Caliway Biopharmaceuticals C, TW0006919004

Caliway Biopharmaceuticals C stock: November 11 results follow TWD 330.27 million loss

Published on 10/23/2026 at 15:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue was TWD 3.57 million for June. Caliway Biopharmaceuticals C stock stood at TWD 73.80 on October 22, 2026, down 2.89 percent on TWSE.

Reporting date and financial scale

Caliway Biopharmaceuticals C is due to report on November 11, 2026, after a TWD 330.27 million first-half net loss.
Second-quarter revenue reached TWD 3.57 million, while first-half revenue declined 70.79 percent year over year.
Caliway Biopharmaceuticals C stock stood at TWD 73.80 on October 22, 2026, down 2.89 percent from TWD 76.00.
The company had a TWD 114.9 billion market capitalization on October 22, 2026.

Caliway Biopharmaceuticals C, TW0006919004, Illustration mit AI erstellt.

Caliway Biopharmaceuticals C (ISIN TW0006919004) is due to report its next results on November 11, 2026, after a first-half net loss of TWD 330.27 million. Investing.com lists November 11, 2026 as the next reporting date, while Quartr reports the first-half loss in its October 7, 2026 earnings summary. The latest dated Taiwan quote was TWD 73.80 on October 22, 2026, down 2.89 percent from TWD 76.00.

Revenue remains small

The financial profile is dominated by research spending rather than product sales. In the first half of 2026, revenue was TWD 3.568 million, compared with TWD 12.212 million in the same period of 2025, a decline of 70.79 percent. Quartr also reported that the first-half net loss narrowed from TWD 424.378 million to TWD 330.270 million, an improvement of 22.18 percent.

Price position in Taiwan

The October 22 quote came with 2,739,218 shares traded and a market price of TWD 73.80. The company had a TWD 114.9 billion market capitalization on that date. The latest available quote was below the previous Taiwan close of TWD 76.00, giving the stock a daily decline of 2.89 percent.

Valuation and reporting date

The scheduled November 11, 2026 results are the next dated company event. Investing.com shows consensus revenue of TWD 8.00 million and consensus earnings per share of minus TWD 0.25 for the reporting period ending September 2026. Those figures are expectations rather than reported results.

What does the loss mean for scale?

Caliway's first-half revenue of TWD 3.568 million was small beside the TWD 330.270 million net loss, with revenue covering only 1.08 percent of the loss in absolute terms. The comparison underlines the company's present financial profile: development costs remain the central measurable figure, while commercial revenue is still limited. The second-quarter loss was TWD 222.516 million, following a first-quarter loss of TWD 107.754 million.

Stock stays below its prior close

Caliway Biopharmaceuticals C stock last stood at TWD 73.80 on the Taiwan Stock Exchange on October 22, 2026, down 2.89 percent from TWD 76.00. The next results date gives investors a defined checkpoint for revenue, loss and development spending.